Zhuhai Kairui Bio completed nearly 100 million yuan in Series A financing

It was reported on November 1 that Zhuhai Kairui has recently successfully completed a financing of nearly 100 million yuan. The investors include Juke Investment, Yanghe Investment, Gree Industrial Investment, Jiete Biotechnology and Dingsheng Yunchuang.

Zhuhai Kairui Biotechnology Co., Ltd. was established in 2014. The company focuses on the development of serum-free cell culture technology products with international leading levels, provides high-quality technical services, and ensures sustainable product development and production requirements for domestic biomedical product research and development institutions. complete technical solutions. The company’s core technical team consists of a number of senior scientists, including the founder of serum-free cell culture technology and an international authority, senior technical experts from large international pharmaceutical companies with more than 20 years of experience in new drug product development, and many years of experience in internationally renowned biomedical research. Scientists with institutional research experience.

At present, the product development of Zhuhai Kairui cell culture technology mainly focuses on four product areas, namely monoclonal antibodies and recombinant proteins, cell therapy and gene therapy, precise diagnosis, and human and veterinary vaccines. The company provides serum-free cell culture technology products for R&D and production in these four product areas, including culture media, nutritional supplements, cell adhesion factors, recombinant protein growth factors, interleukins and other cell culture supporting reagents. The company’s comprehensive product line is in It is in a leading position among similar technology product companies at home and abroad, covering more than 400 industrial customers and achieving profitable growth for several consecutive years.